Press release
Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion
The Key Hypophosphatasia Companies in the market include - PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others.DelveInsight's "Hypophosphatasia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hypophosphatasia, historical and forecasted epidemiology as well as the Hypophosphatasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hypophosphatasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypophosphatasia Market Forecast [https://www.delveinsight.com/report-store/hypophosphatasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Hypophosphatasia Market Report:
*
The Hypophosphatasia market size was valued at ~USD 880 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
The pipeline for Hypophosphatasia is not very robust, consisting of REC-01, ALXN1850, and others which are expected to launch during the forecast period [2022-2032]
*
According to DelveInsight's analysis, the diagnosed prevalent cases of Hypophosphatasia in the 7MM were estimated to be around 6,500 in 2023. This number is expected to rise by 2034 due to increased disease awareness among healthcare professionals and the general public worldwide.
*
In 2023, the US reported the highest diagnosed prevalence of hypophosphatasia among the 7MM, with approximately 6,000 cases. These numbers are expected to grow from 2024 to 2034, largely due to advancements in genetic testing that have enabled expanded newborn screening programs across the country.
*
Among the EU4 countries and the UK, Germany reported the highest number of diagnosed hypophosphatasia cases, with about 84 cases, followed by France with 69 cases, and the UK with 68 cases. These numbers are expected to increase by 2034, driven by a heightened focus on research and clinical trials for the disease.
*
In the UK, mild hypophosphatasia cases accounted for nearly 82%, moderate cases for 16%, and severe cases for 2% in 2023. The number of cases for each severity level is expected to rise by 2034.
*
Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others
*
Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others
*
The Hypophosphatasia epidemiology based on severity-specific cases analyzed that mild Hypophosphatasia was most prevalent in the US, followed by moderate and severe Hypophosphatasia
*
The Hypophosphatasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypophosphatasia pipeline products will significantly revolutionize the Hypophosphatasia market dynamics.
Hypophosphatasia Overview
Hypophosphatasia is defined as a rare, genetic metabolic disorder characterized by impaired mineralization of bones and teeth, according to National Organization for Rare Disorders (NORD). Defective mineralization results in bones that are soft and prone to fracture and deformity and it also leads to tooth loss. Depending on the specific form, it can be inherited in an autosomal recessive or dominant manner.
Get a Free sample for the Hypophosphatasia Market Report
https://www.delveinsight.com/sample-request/hypophosphatasia-market [https://www.delveinsight.com/sample-request/hypophosphatasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypophosphatasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypophosphatasia Epidemiology Segmentation:
The Hypophosphatasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Hypophosphatasia
*
Prevalent Cases of Hypophosphatasia by severity
*
Gender-specific Prevalence of Hypophosphatasia
*
Diagnosed Cases of Episodic and Chronic Hypophosphatasia
Download the report to understand which factors are driving Hypophosphatasia epidemiology trends @ Hypophosphatasia Epidemiology Forecast [https://www.delveinsight.com/report-store/hypophosphatasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypophosphatasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypophosphatasia market or expected to get launched during the study period. The analysis covers Hypophosphatasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypophosphatasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypophosphatasia Therapies and Key Companies
*
REC-01: PuREC
*
ALXN1850: AstraZeneca
*
BPS804: Ultragenyx Pharmaceutical Inc
Discover more about therapies set to grab major Hypophosphatasia market share @ Hypophosphatasia Treatment Market [https://www.delveinsight.com/report-store/hypophosphatasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypophosphatasia Market Strengths
*
Advancements in understanding the pathophysiology and genetics of Hypophosphatasia, thereby elucidating new targets for treatment
*
The approval of ERT by various regulatory authorities is a game changer, improving clinical manifestations, survival, and QoL
Hypophosphatasia Market Barriers
*
Developing specific biochemical biomarker-based assays with an increased understanding of differential diagnosis among physicians will lead to improvements in diagnosis, thus opening the windows of opportunity for new treatment options
*
There is a need for pharmacotherapeutic interventions for milder adult-onset of disease, which has little mortality and a high disease burden
Scope of the Hypophosphatasia Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others
*
Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others
*
Hypophosphatasia Therapeutic Assessment: Hypophosphatasia current marketed and Hypophosphatasia emerging therapies
*
Hypophosphatasia Market Dynamics: Hypophosphatasia market drivers and Hypophosphatasia market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Hypophosphatasia Unmet Needs, KOL's views, Analyst's views, Hypophosphatasia Market Access and Reimbursement
To know more about Hypophosphatasia companies working in the treatment market, visit @ Hypophosphatasia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/hypophosphatasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hypophosphatasia Market Report Introduction
2. Executive Summary for Hypophosphatasia
3. SWOT analysis of Hypophosphatasia
4. Hypophosphatasia Patient Share (%) Overview at a Glance
5. Hypophosphatasia Market Overview at a Glance
6. Hypophosphatasia Disease Background and Overview
7. Hypophosphatasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypophosphatasia
9. Hypophosphatasia Current Treatment and Medical Practices
10. Hypophosphatasia Unmet Needs
11. Hypophosphatasia Emerging Therapies
12. Hypophosphatasia Market Outlook
13. Country-Wise Hypophosphatasia Market Analysis (2020-2034)
14. Hypophosphatasia Market Access and Reimbursement of Therapies
15. Hypophosphatasia Market Drivers
16. Hypophosphatasia Market Barriers
17. Hypophosphatasia Appendix
18. Hypophosphatasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypophosphatasia-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-purec-astrazeneca-ultragenyx-pharma-inc-alexion]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion here
News-ID: 3783453 • Views: …
More Releases from ABNewswire

Acute Myeloid Leukemia Market to Evolve Rapidly Over the Next Decade by 2034, De …
The Key Acute Myeloid Leukemia Companies in the market include - SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others.
The Acute Myeloid Leukemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Myeloid Leukemia pipeline products will significantly revolutionize the Acute Myeloid Leukemia market dynamics.
DelveInsight's…

Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, De …
The Key Pancreatic Cancer Companies in the market include - AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others.
The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and…

Hereditary Transthyretin Amyloidosis (hATTR) Market to Witness Promising Upswing …
The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others.
DelveInsight's "Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany,…

Metastatic HR+/HER2 Breast Cancer Market Positioned for Accelerated Development …
The Key Metastatic HR+/HER2 Breast Cancer Companies in the market include - Novartis, Arvinas, Olema Pharmaceuticals, Sichuan Baili Pharmaceutical, Ana C Garrido-Castro, MD, Fudan University, SynDevRx, Inc., Gilead Sciences, Puma Biotechnology, Inc., Adrienne G. Waks, Carrick Therapeutics Limited, and others.
DelveInsight's "Metastatic HR+/HER2 Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Metastatic HR+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the Metastatic…
More Releases for Hypophosphatasia
Hypophosphatasia Market New Product Development & Latest Trends
Introduction
Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by deficient activity of the enzyme tissue-nonspecific alkaline phosphatase (TNSALP). The condition impairs bone and teeth mineralization, leading to skeletal deformities, fractures, premature tooth loss, muscle weakness, and in severe cases, respiratory failure. Its wide clinical spectrum-from perinatal to adult onset-creates significant medical challenges.
For decades, management was largely supportive, focusing on symptom relief. However, the introduction of enzyme replacement therapy (ERT)…
Comprehensive 2025 Hypophosphatasia Treatment Market Overview: Trends, Forecasts …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Is the Expected CAGR for the Hypophosphatasia Treatment Market Through 2025?
There has been consistent expansion in the market size for hypophosphatasia treatments in recent years. The market, worth $2.83 billion in 2024, will escalate to $2.96 billion by 2025, with a Compound Annual Growth Rate (CAGR) of 4.6%. Factors such as narrow…
Hypophosphatasia Treatment Market: A Complete Guide For Research
Global Hypophosphatasia Treatment Market reached US$ 841.9 million in 2023 and is expected to reach US$ 2785.10 million by 2031, growing at a CAGR of 16.1% during the forecast period 2024-2031
Hypophosphatasia Treatment Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models,…
Hypophosphatasia Market Insights, Epidemiology, and Market Forecast 2034 by Delv …
"The market size of Hypophosphatasia is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as CENTOGENE GmbH Rostock, Alexion Pharmaceuticals, Inc., AM-Pharma, Ultragenyx Pharmaceutical Inc, AstraZeneca, AM Pharma, PuREC"
[Nevada, United States] - DelveInsight's "Hypophosphatasia Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Hypophosphatasia, covering historical and predicted epidemiology, market trends, and…
Hypophosphatasia Treatment Market Size, Share 2033
The new report published by The Business Research Company, titled ""Hypophosphatasia Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the hypophosphatasia treatment market size has grown steadily in recent years. It will grow from $2.68 billion in 2023…
Hypophosphatasia Treatment Market Insights, Size, Forecast, Growth, Trends 2024- …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Hypophosphatasia Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.45 billion In 2028 At…